Co-sulfamethoxazole Tablets

This product is a sulfonamide antibacterial drug, a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP). It has good antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Proteus, Morganella, Shigella and other Enterobacteriaceae, gonococci, Neisseria meningitidis, and Haemophilus influenzae. In particular, the antibacterial effect on Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus is significantly enhanced compared with SMZ alone. In addition, it also has good antimicrobial activity against Chlamydia trachomatis, Nocardia asteroides, protozoa, and Toxoplasma in vitro. The mechanism of action of this product is: SMZ acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis, and TMP acts on the second step of folic acid anabolism, selectively inhibiting the action of dihydrofolate reductase. The combination of the two can double-block the folic acid metabolism of bacteria. The synergistic antibacterial effect of this product is stronger than that of a single drug, and the number of resistant strains to it is reduced. However, in recent years, the resistance of bacteria to this product has also been increasing.

Sulfadiazine tablets 0.4g, trimethoprim 0.08g

This product is white tablets

The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or Shigella sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii or adults infected with HIV whose CD4 lymphocyte count is ≤200/mm3 or less than the total lymphocyte count can be used.

1 Common dosage for adults: 160 mg of trimethoprim and 800 mg of sulfamethoxazole for the treatment of bacterial infections, taken once every 12 hours. For the treatment of Pneumocystis carinii pneumonia, 3.75-5 mg/kg of trimethoprim and 18.75-25 mg/kg of sulfamethoxazole are taken once every 6 hours. Preventive medication for adults: initially give 160 mg of trimethoprim and 800 mg of sulfamethoxazole twice a day, followed by the same dose once a day, or 3 times a week. 2 Common dosage for children: contraindicated for infants under 2 months old. For the treatment of bacterial infections, infants over 2 months old and weighing less than 40 kg are given SMZ 20-30 mg/kg and TMP 4-6 mg/kg orally according to body weight, once every 12 hours; the dosage for children weighing >40 kg is the same as the common dosage for adults. For the treatment of parasitic infections such as Pneumocystis carinii pneumonia, SMZ 18.75-25 mg/kg and TMP 3.75-5 mg/kg are taken orally once every 6 hours according to body weight. The course of treatment for acute exacerbation of chronic bronchitis is at least 10-14 days; the course of treatment for urinary tract infection is 7-10 days; the course of treatment for bacillary dysentery is 5-7 days; the course of treatment for acute otitis media in children is 10 days; the course of treatment for Pneumocystis carinii pneumonia is 14-21 days.

1 Allergic reactions are common. They may manifest as drug eruptions, and in severe cases, exudative erythema multiforme, exfoliative dermatitis, and bullous epidermolysis atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. Anaphylactic shock is occasionally seen. 2 Neutropenia or deficiency, thrombocytopenia, and occasionally aplastic anemia. Patients may present with sore throat, fever, and bleeding tendency. 3 Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children than in adults. 4 Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Neonates have imperfect liver function, so they are more likely to develop hyperbilirubinemia and neonatal jaundice, and kernicterus may occasionally occur. 5 Liver damage. Jaundice and decreased liver function may occur, and in severe cases, acute liver necrosis may occur. 6 Kidney damage. Crystalluria, hematuria, and tubular urine may occur; occasionally, patients may experience serious adverse reactions such as interstitial nephritis or renal tubular necrosis. 7 Nausea, vomiting, decreased appetite, diarrhea, headache, fatigue, etc. Generally, the symptoms are mild and do not affect continued medication. Occasionally, patients develop Clostridium difficile enteritis, and the drug should be discontinued. 8 Occasionally, thyroid enlargement and dysfunction occur. 9 Central nervous system toxicity may occasionally occur, manifested as mental confusion, disorientation, hallucinations, euphoria or depression, and the drug should be discontinued immediately if it occurs. 10 Aseptic meningitis may occasionally occur, with symptoms such as headache, stiff neck, and nausea. Although serious adverse reactions caused by this product are rare, they often involve various organs and can be fatal, such as exudative erythema multiforme, exfoliative dermatitis, epidermolysis bullosa atrophic dermatitis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood system abnormalities.

1. Patients who are allergic to sulfonamides are contraindicated to use this product. 2. Since this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, patients with this disease are contraindicated to use this product. 3. Pregnant and lactating women are contraindicated to use this product. 4. Infants under 2 months old are contraindicated to use this product. 5. Patients with liver and kidney damage are contraindicated to use this product.

1. Urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. Combination with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. Such as leukopenia and thrombocytopenia, etc. If there is an indication for the use of the two drugs together, possible toxic reactions should be closely observed. 5. Long-term combination with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7 When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 8 When used in combination with photosensitive drugs, photosensitization may be additive. 9 Patients receiving this product have an increased need for vitamin K. 10 It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product. The risk of crystalluria increases. 11 This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12 When sulfinpyrazone is used in combination with this product, it can reduce the latter's secretion from the renal tubules, and its blood concentration increases and lasts for a long time, thereby producing toxic reactions. Therefore, the dose of this product may need to be adjusted during or after the application of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of this product should be monitored to help adjust the dose and ensure safe medication. 13 The TMP in this product can inhibit the metabolism of warfarin and enhance its anticoagulant effect. 14 The TMP in this product can increase renal toxicity when used in combination with cyclosporine. 15 When rifampicin is used in combination with this product, the clearance of TMP in this product can be significantly increased and the serum half-life can be shortened. 16 It is not suitable to be used in combination with anti-tumor drugs and 2,4-diaminopyrimidine drugs, nor should it be used between courses of treatment with other folic acid antagonists, because it may cause bone marrow aplasia or megaloblastic anemia. 17 It is not suitable to be used in combination with dapsone, because the blood concentration of both dapsone and TMP in this product can be increased when used in combination. The increase in dapsone concentration increases and aggravates adverse reactions, especially the occurrence of methemoglobinemia. 18 Avoid using it in combination with penicillins, because this product may interfere with the bactericidal effect of such drugs.

Keep away from light and store in sealed container.

Sulfadimethoxazole 0.4g, trimethoprim 80mg

Dalian Making Charm Pharmaceutical Co., Ltd.

• Founded in:

  1996-01-16

• Address:

  No. 89, Shengming 1st Road, ShuangDang, Dalian Economic and Technological Development Zone, Liaoning Province

• Tax NO.:

  9121021324377529XN

• Registered Funds:

  55 million yuan

• Website:

  Log in to view

• Email:

  Log in to view